Edison valuation

Oct 30th 2014 - Edison Investment Research today published a report on Mesoblast entitled "Pipeline Progress". In summary, the report says: Mesoblast’s product pipeline continues to mature as key milestones are met. The filing of MSC-100-IV in graft vs host disease (GvHD) in Japan in early October marks its first product submission. Phase III trials started early this year for MPC-150-IM in congestive heart failure (CHF), while Phase III trials for MPV-06-ID in low back pain are expected to start by the end of 2014 following a productive meeting mid-year with the FDA. Mesoblast recently announced a new tiered product structure, whereby resources are being funnelled into its key late-stage products. We value Mesoblast at A$3.16bn (A$9.31/diluted share), more than twice its current share price. - See more at: http://www.stockopedia.com/research/pipeline-progress-87332/#sthash.aZbYq37C.EVvkQ7Xk.dpuf